<DOC>
	<DOC>NCT01283776</DOC>
	<brief_summary>A phase II clinical study to assess the efficacy of post-transplantation cyclophosphamide as single-agent GvHD prophylaxis after allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma or lymphoma and to describe the influence of the modified immunosuppression concept on relapse rates, minimal residual disease, immune reconstitution and chimerism.</brief_summary>
	<brief_title>Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Patients with multiple myeloma, NonHodgkin's lymphoma or Hodgkin's disease after allogeneic stem cell transplantation with reduced intensity conditioning Written informed consent No uncontrolled infections Severe organ dysfunction defined as: Cardiac left ventricular ejection fraction (LVEF) of less than 35% diffusing lung capacity (DLCO) of less than 40% total lung capacity (TLC) of less than 40% forced expiratory volume (FEV1) of less than 40% total bilirubin &gt;3mg/dl creatinineclearance of less than 40 ml/min pregnancy or breast feeding participation in other experimental drug trials</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>